Actinium Pharmaceuticals Inc Total Liabilities
Actinium Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Actinium Pharmaceuticals Inc (ATNM) has total liabilities worth $43.13 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ATNM financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Actinium Pharmaceuticals Inc (2006–2025)
Total liabilities of Actinium Pharmaceuticals Inc from 2006 to 2025. This chart illustrates how Actinium Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore ATNM long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Actinium Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Actinium Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Revoil S.A
AT:REVOIL
|
Greece | €103.35 Million |
|
SK D&D Co Ltd
KO:210980
|
Korea | ₩1.12 Trillion |
|
Brand 24 SA
WAR:B24
|
Poland | zł15.03 Million |
|
Pacgold Ltd
AU:PGO
|
Australia | AU$4.89 Million |
|
Green Impact Partners Inc
V:GIP
|
Canada | CA$73.28 Million |
|
Wiable Corp
KQ:065530
|
Korea | ₩66.64 Billion |
|
GROUP PAREF INH. EO 25
F:G5I
|
Germany | €102.63 Million |
|
Ginni Filaments Limited
NSE:GINNIFILA
|
India | Rs-2.36 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Actinium Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Actinium Pharmaceuticals Inc.
Liquidity & Leverage Metrics
Actinium Pharmaceuticals Inc Total Liabilities Ratios Explained
Actinium Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 18.72 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.95 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Actinium Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Actinium Pharmaceuticals Inc (2006–2025)
The table below shows the annual total liabilities of Actinium Pharmaceuticals Inc from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $43.94 Million | -0.45% |
| 2024-12-31 | $44.14 Million | -2.05% |
| 2023-12-31 | $45.07 Million | -5.54% |
| 2022-12-31 | $47.71 Million | +597.22% |
| 2021-12-31 | $6.84 Million | +34.76% |
| 2020-12-31 | $5.08 Million | -15.73% |
| 2019-12-31 | $6.03 Million | -0.83% |
| 2018-12-31 | $6.08 Million | +30.23% |
| 2017-12-31 | $4.67 Million | +3.22% |
| 2016-12-31 | $4.52 Million | -2.02% |
| 2015-12-31 | $4.61 Million | -51.39% |
| 2014-12-31 | $9.49 Million | +29.57% |
| 2013-12-31 | $7.33 Million | +57.76% |
| 2012-12-31 | $4.64 Million | +5396.26% |
| 2011-12-31 | $84.48K | -10.86% |
| 2010-12-31 | $94.77K | -3.70% |
| 2009-12-31 | $98.41K | +29.19% |
| 2008-12-31 | $76.18K | +92.19% |
| 2007-12-31 | $39.64K | +110.05% |
| 2006-12-31 | $18.87K | -- |
About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular… Read more